[Evaluation of anginine in the treatment of cerebrovascular disorders (preliminary report)].
The effect of Anginin was assessed in 10 patients with cerebrovascular diseases. Anginin was administered in daily doses of 1.5 g. during a mean time of 5.25 months. The duration of follow-up before, during and after treatment was 2 years. A favourable effect of Anginin was observed on such symptoms as dizziness, disturbances of recent memory, mental fatiguability, difficulties in concentration and irritability. EEG investigations demonstrated a rise in the index of alpha waves, increased frequency and amplitude of alpha waves, and normalization of tracings in cases with pathological abnormalities. The basic laboratory investigations failed to reveal any significant changes. Side effects included transient dyspeptic symptoms were in 5 patients.
D000368:Aged; D000513:Alpha Rhythm; D002219:Carbamates / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D003248:Constipation / Q000139:chemically induced; D003700:Delta Rhythm; D003967:Diarrhea / Q000139:chemically induced; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006801:Humans; D002534:Hypoxia, Brain / Q000188:drug therapy; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy; D002542:Intracranial Embolism and Thrombosis / Q000188:drug therapy; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011727:Pyridinolcarbamate / Q000627:therapeutic use*; D013826:Theta Rhythm
D002219:Carbamates; D011727:Pyridinolcarbamate
Ocena działania angininy w chorobach naczyniowych mózgu (doniesienie wstepne)